Develops and commercializes an innovative early cancer detection
and disease management platform based on its revolutionary
discovery that cancer causes alterations in the function and
composition of intestinal micro-flora in a quantifiable and
measurable manner.
Employees: 12
Main Markets:
Cancer diagnostic market.
Overview
MASSIS EARLY DETECTION LTD. is a fully owned research and
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
development subsidiary of Era-Massis Inc., a Delaware USA
corporation established in 1999.
MASSIS develops and commercializes an innovative early cancer
detection and disease management platform based on its
revolutionary discovery that cancer causes alterations in the
function and composition of intestinal micro-flora in a
quantifiable and measurable manner.
To date, MASSIS has developed a proprietary bioassay based on its
core technology that has demonstrated effective clinical outcomes
in vitro and during preliminary clinical studies. The Company is
currently finalizing prototype development for its first product
that will detect colorectal cancer early. MASSIS expects a
platform of product opportunities, both diagnostic and
therapeutic, to be derived from its core technology in years to
come.
